Lacrimal stents have been used in columnar lining of the lacrimal sac and nasolacrimal duct. It is composed of folding tube which is surrounded. During the lacrimal pump function a specialized part of orbicularis oculi such as antero-inferiorly by Horner's muscle are participating more. Lacrimal intubation has become a very common surgical procedure for congenital nasolacrimal duct obstruction that does not respond to conservative medical treatment or with failed probing. Various types of Lacrimal Duct Stent Tube devices are available in the Lacrimal Duct Stent Tube market such as monocanalicular lacrimal duct stent tube, bicanalicular lacrimal duct stent tube. Out of this device bianalicular lacrimal duct is most commonly used device for bicanalicular lacrimal intubation is a successful treatment for the younger the age of the children the higher the success rate and children with nasolacrimal duct obstruction. Bicanalicular lacrimal tubes have two probes with an intervening stent. One probe is passed through the upper punctum and the other pass through the lower punctum. The probes are removed, and the free ends of the silicone tube are tied in the nose and sometimes secured with a suture. The longer the duration of the tube retention give the improved outcome between 3 and 12 months children’s.
COVID-19 Scenario Analysis:
To take care of infected population the demand for medical supplies is increasing. Respiratory support devices such as atomizer, life-support machine, oxygen generator, and monitor are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. With rise in number of COVID-19 cases worldwide, the need for medical supplies keeps on rising among, both from healthcare professionals and civil population for precautionary measures.
Manufacturers of these products have a chance to capitalize this increased demand of medical supplies to ensure adequate and continuous supply of personal protective equipment in the market.
Ongoing spread of covid-19 pandemic impacted the growth of lacrimal duct stent tube devices market. Government undertaken initiative such as they have set up financial relief packages for healthcare professionals across the globe which being impacted by the global coronavirus pandemic. Government also providing the guidelines for physician that have also been encouraging physician to stop providing all treatments of a non-urgent nature, for the foreseeable future, till the outbreak is brought under control. This trend is likely to hinder the global market for lacrimal duct stent tubes in the near future. Reducing demand for devices will impact growth of market and production of devices. With advances in ophthalmology technology, recovery of the industry is likely to be sluggish in the near future, as countries seek to conserve their medical supply stocks, for applications that have a higher priority.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
Hospitals the major end user of lacrimal duct stent tube devices market will hold a larger market share of the global lacrimal duct stent tube market driven by expanding numbers of retinal disease cases.
Globally, North America is hold the largest lacrimal duct stent tube market share and considered as a most dominance region owing to increasing awareness among the population regarding lacrimal duct and increasing medical devices industries collaboration with hospitals and clinics. Whereas, Europe is considered as an second largest market due to the increasing awareness amongst the patient population regarding surgical procedure and lacrimal duct stent tube devices
However, Asia-Pacific expected to drive the market growth rate due to the increasing number of appropriate health professionals and rising demand for medical devices regarding lacrimal duct stent tube. The factor that drive the growth of lacrimal duct stent tube market such as rapid increasing patient pool, increasing investment on the healthcare sector, increasing advancements of medical device, increasing demand for non-invasive surgeries, increasing incidences of retinal diseases, growing promotional activities about nasolacrimal duct obstruction management for health care professionals, and rising awareness amongst the people about various types of surgeries regarding lacrimal duct obstruction. The major factor such as high cost of treatment device, increasing risk of complications among patients of younger demographics, stringent government regulation and the risk of corneal scratch from treatment procedures are restraining the global lacrimal duct stent tube market. Major challenges face by market player such as reducing cost devices, reducing the demand for lacrimal duct stent tube associated devices.
New Product launch to flourish the market:
Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. In 2019, “FCI Ophthalmic” has launched “Ophtacath®” device. It is a lacrimal duct balloon catheter kit used for the dilation of an obstructed nasolacrimal duct. In 2019, “Kaneka Pharma America LLC”, has launched “LACRIFLOW CL” is a Nasolacrimal Duct Obstruction (NLDO) device. LACRIFLOW CL can help physician to treat Nasolacrimal Duct Obstruction (NLDO). This device enhanced the operational flexibility and hydrophilic coating for physician ease and patient comfort. In 2019, “Aurolab” has launched “Lacrimal Incubation Set” used in conventional dacryocysto rhinostomy (DCR) procedure. This device comprises of two flexible stainless steel probes attached through a hollow medical graded silicone tube.
In 2019, “Gunther Weiss Scientific” has launched “Conjunctivo dacryocysto rhinostomy” (CDCR) with Jones tube placement. This is generally performed to bypass the lacrimal canaliculi and sac, providing a direct route for tears to enter the nasal cavity in cases of upper system blockage
Key benefits of the report:
- This study presents the analytical depiction of the global lacrimal duct stent tube market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global lacrimal duct stent tube market share.
- The current market is quantitatively analyzed to highlight the global lacrimal duct stent tube market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global lacrimal duct stent tube market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Lacrimal Duct Stent Tube Market research report:
- Who are the leading market players active in lacrimal duct stent tube?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that will help in taking further strategic steps?
Lacrimal Duct Stent Tube Market Report Highlights
Key Market Players
FCI Ophthalmic,, Kaneka Pharma America LLC,, Beaver Visitec International., Aurolab,, Sinopsys Surgical,, Cook Medical,, Gunther Weiss Scientific,, Bess Medizintechnik GmbH,, Fruida,